Professional Seasonal Analysis for Trading

Insight Molecular Diagnostics Inc. - Common Stock (IMDX)

Seasonality Analysis

Stocks 11 Years Analyzed

Insight Molecular Diagnostics Inc. - Common Stock Annual Seasonality Statistics

3.74%
Avg Annual Return
38.4%
Avg Monthly Win Rate
5/12
Positive Months
11
Years Analyzed

Insight Molecular Diagnostics Inc. - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January BEST 20.92%
36%
Weak
February -7.45%
9%
Very Weak
March -0.79%
73%
Weak
April -0.31%
36%
Very Weak
May 1.25%
40%
Weak
June -8.25%
30%
Very Weak
July WORST -10.14%
20%
Very Weak
August 2.40%
50%
Weak
September 9.44%
60%
Moderate
October -2.60%
30%
Very Weak
November 2.05%
40%
Weak
December -2.78%
36%
Very Weak

Insight Molecular Diagnostics Inc. - Common Stock 2026 vs Historical Pattern

Current Position
17.58
Historical Avg Position
47.11
Deviation
-29.53
Performance
Significantly Below Average

Insight Molecular Diagnostics Inc. - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for IMDX with overlay patterns, custom date ranges, and more.

Create Free Account

Insight Molecular Diagnostics Inc. - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Insight Molecular Diagnostics Inc. - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for IMDX across multiple timeframes.

Create Free Account

About Insight Molecular Diagnostics Inc. - Common Stock (IMDX) Seasonality

Insight Molecular Diagnostics Inc. - Common Stock (IMDX) has been analyzed using 11 years of historical data to identify seasonal patterns. Classified under Stocks, Insight Molecular Diagnostics Inc. - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Insight Molecular Diagnostics Inc. - Common Stock is historically January, with an average return of 20.92% and a win rate of 36%. Conversely, July tends to be the weakest month, averaging -10.14% return.

Looking at the full calendar year, Insight Molecular Diagnostics Inc. - Common Stock has an average annual return of 3.74% with an overall monthly win rate of 38.4%. Out of 12 months, 5 typically show positive average returns.

The seasonal pattern for Insight Molecular Diagnostics Inc. - Common Stock has a consistency score of 54 (Fair), based on 12 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Insight Molecular Diagnostics Inc. - Common Stock Seasonality FAQ

What is the best month to buy Insight Molecular Diagnostics Inc. - Common Stock (IMDX)?

Historically, January has been the best month for Insight Molecular Diagnostics Inc. - Common Stock, with an average return of 20.92% and a win rate of 36%. However, past performance does not guarantee future results.

What is the worst month for Insight Molecular Diagnostics Inc. - Common Stock (IMDX)?

Based on historical data, July has been the weakest month for Insight Molecular Diagnostics Inc. - Common Stock, with an average return of -10.14%. This is a historical observation and does not guarantee future results.

How reliable is IMDX seasonality data?

The seasonality analysis for Insight Molecular Diagnostics Inc. - Common Stock is based on 11 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Insight Molecular Diagnostics Inc. - Common Stock seasonality in my trading?

Use Insight Molecular Diagnostics Inc. - Common Stock (IMDX) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.